A Study of 8 Patients with Polycythaemia Vera: The Impact of JAK2 (V617F) Mutation on Diagnosis
DOI:
https://doi.org/10.15379/2408-9877.2018.05.02.01Keywords:
Polycythaemia vera, JAK2 mutation, Clinicopathological diagnosis, UUTH, Nigeria.Abstract
Background: The discovery of the Janus Kinase 2 (JAK2) gene mutation provides a new molecular approach for the diagnosis of polycythaemia vera (PV).
We studied retrospectively patients with a diagnosis of PV at initial presentation to the hospital. They were followed up for an initial period of 2 months.
Objective: The objectives were to access the clinicopathological characteristics, impact of identification of JAK2 mutation on diagnosis and treatment strategies.
Result: Of the 6 patients with complete medical records, 3 were males (50%). The mean haematocrit values were 59.7%, males had a value of 60.3% while females a values of 59.0%. The total WBC count was 8.8 x 109/L while the platelet count was 463.5 x 109/L. None of the patients’ had splenomegaly, all had pruritus. During follow up the mean haematocrit values were 52.3%, males had a value of 55.8% while females a values of 48.7%. The total WBC count was 11.1 x 109/L while the platelet count was 652.1 x 109/L. There was a reduction in the haematocrit value but the white blood cell and platelet counts remained high.
Of the 5 patients who had molecular analysis done, 4(80%) had the JAK2 mutation while in 1 (20%) the mutation was not detected. The results of the molecular analysis done in a regional laboratory were received after an average of 21 days.
The patients were treated with phlebotomy and hydroxyurea. One patient with increasing thrombocytosis had clopidogrel initiated. 3 patients were lost in the follow-up period once there was clinical improvement, at 6 months and 1 year only 1 patient was left in follow-up.
Conclusion: The lag time for obtaining results of molecular analysis was long, which made diagnosis and management on clinicalbasis.
This highlights the need for the upgrading of more laboratories to acquire molecular technology for improved patients care and diagnostic accuracy.
References
Ola Landgren, Lynn R Goldin, Sigurdur Y Kristinsson, Elin A Helgadottir, Jan Samuelsson and Magnus Bjorkholn. Increased risk of Polycythaemia Vera, Essential Thrombocythaemia and Myelofibrosis among 24577 first –degree relatives of 11039 patients with Myeloproliferative neoplasms in Sweden. Blood 2008; 112(6): 2199-2204. https://doi.org/10.1182/blood-2008-03-143602
Jerry L Spivak, Micheal Considine, Donna M Williams, Conover C Talbot Jr, Ophelia Rogers, Alison R Moliterno, ChunfaJie and Micheal F Ochs. Two Clinical Phenotypes in Polycythemia Vera. The New EngL J of Med 2014; 371(9): 808-817. https://doi.org/10.1056/NEJMoa1403141
Muhammad Shariq Shaikh, Mohammad Usman Shaikh, Salman Naseem Adil, Mohammad Khurshid, Zeehan Ansar Ahmed. Clinico-Pathology profile and outcomes of patients with Polycythaemia Vera, Essential Thrombocythaemia and Idiopathic Myelofibrosis: A Tertiary Care Centre Experience from Southern Pakistan. J Ayub Med Coll Abbottabad 2016; 28(2): 293-297.
Tiong IS, Casolari DA, Nuguyen T, Van Velzen MJM, Ambler K, D’Andra RJ et al. Masked PV is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythemia vera. Blood Cancer J 2016. 6, e 459: doi10. 1038/bcj. 2016.70
Grzegorz Helbig, Agata Wieczorkiewicz, Malgorzata Krawczyk, Darusz Kata, Marek Seweryn, Wlodzimierz Mendrek et al. The JAK2 V617F point mutation correlates with clinical phenotype in patients with polycythemia vera and essential thrombocythemia contemporary oncology 2008; 12 (10): 452-454.
Jerry L Spivak and Richard T Silver. The revised World Health Organization diagnostic criteria for polycythaemiavera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008; 112(2): 231-238. https://doi.org/10.1182/blood-2007-12-128454
Koushik Gudavalli, Shilpa Chikati, Mohan R Jakkamputi, Kamal L Behera, Swarne LD Gambir. An Uncommon presentation of Polycythemia Vera as Ischemic Stroke – A Rare Case Report. International J of Scientific Research 2014; 3(5): 455-457. https://doi.org/10.15373/22778179/MAY2014/144
Ming Cao, Randell J Olsen, Youli Zu Polycythaemia Vera, New Clinicopathologic Perspective. Arch Pathol Lab Med 2006; 130: 1126-1132.
Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W. Current diagnostic criteria for the Chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), Polycythemia Vera (PV) and Chronic idiopathic myelofibrosis CIMF. Pathol Biol 2007; 55(2): 92-104. https://doi.org/10.1016/j.patbio.2006.06.002
Jong-Ha Yoo, Tae Sung Park, Ho-Young Maeng, Young-Kyu Sun, Young-Ah Kim, Joeng-HaeKie et al. JAK2 V617F/C618R Mutation in a Patient with PV: A case study and review of Literature. Cancer genet. cytogenet 2008.09.010 dio.org/10.1016/
Yu - Min Yeh, Yi - Lin Chen, Hsieh -Yin Cheng, Wu - Chou Su, Nan - Haw Chow, Tsai - Yun Chen et al. High percentage of JAK2 Exon 12 mutation in Asian Patients with Polycythemia Vera. Am. J Clin Pathol 2010; 134: 266-270. https://doi.org/10.1309/AJCPK7KGOWPHYWM0
Linda M Scott, Wei Tong, Ross L Levire, Mike A Scott et al. JAK2 Exon 12 mutation in PV and Idiopathic Erythrocytosis. N. Engl. J Med 2007; 356: 459-468. https://doi.org/10.1056/NEJMoa065202
Leonardo Caires dos Santos, Juliana Correa da Costa Ribeiro, Neusa Pereira Silva, Janete Cerutti, Maria Regina Regis da Silva, Maria De Lourdes Lopes Ferrari Chauffaille. Cytogenetics, JAK2 and MPL mutations in PV, Primary Myelofibrosis and essential thrombocythemia. Rev Bras Hematol Hemoter 2011; 33(6): 417-424. https://doi.org/10.5581/1516-8484.20110116
James W Vardiman, Juergen Thiele, Daniel a. Arber, Richard D Brunning, Micheal J Borowit2, Anna Porwit et al. The 2008 revision of World Health Organization (WHO) classification of the myeloid neoplasms and acute leukaemia: rational and important changes. Blood 2009; 114: 937-951. https://doi.org/10.1182/blood-2009-03-209262
Akpan IS, Ekanem AM. Pattern of Haematological Malignancies among Adult Nigerians Attending a Tertiary Hospital in South south Nigerian: Eight years Review. W. J Biomed Res 2016; 3(1): 17-23.
NIA A OO, B GN, H NKD, O CE. The Epidemiology of Haematological Malignancies at the University of Benin Teaching Hospital: A Ten- year Retrospective Study. The Internet Journal of Epidemiology 2010; 9 (2):
Babatunde A, Amiwero C, Olatunji P, Durotoye I. Pattern of Hematological Malignancies in Ilorin, Nigeria: A ten year Review. The Internet Journal of Haematology 2008; 5 (2). ispub- article13470.
Baruch Modan. An epidermiological study of Polycythemia Vera. Blood 1965; 26(5): 657-667.
Xiaomei Ma, Gary Vanasse, Brenda Cartmel, Yun Wangand H. Andrew Selinger. Prevalence of polycythemia vera and essential thrombocythemia. Am. J of Haematol 2008; 83: 359-362. https://doi.org/10.1002/ajh.21129
Passamonti F, Rumi E, Pietra D, Boveri E, Arcaini L, Roncoroni E et al. A prospective study of 338 patients with Polycythaemiavera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24: 1574-1579. https://doi.org/10.1038/leu.2010.148
Downloads
Published
Issue
Section
License
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .